Affiliation:
1. Cancer and Translational Research Lab, Dr. D.Y. Patil Biotechnology & Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, 411033, India
Abstract
In recent, curiosity is at the forefront to understand the complexity of cancer driven
by genetic, molecular and epigenetic programming due to life style, environmental pressure and
metabolite adaptations. On the other hand, complex and heterogeneous nature of cancer is
linked to the metabolic and molecular landscape of diabetic complications. This Letter to editor
connects the dots and highlights the need to view cancer beyond the mirror of genetic and
epigenetic aberration as metabolic disturbances. In this commentary, the author highlights the
major contributions from two elegant papers from Cha et al. (2018) and Wu et al. (2018) by
delineating molecular pathways that lead to the potential use of anti-diabetic drug metformin
and other potential repurposing drugs towards cancer therapeutics.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Oncology,Molecular Medicine
Reference10 articles.
1. Prasad NK. Two diseases with one hit: Inhibiting a potential diabetes target to reduce cancer risk and to improve anti-cancer therapy.
2. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation.
4. Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
5. Salis O, Bedir A, Ozdemir T, Okuyucu A, Alacam H. The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line.